Does a targeting ligand influence nanoparticle tumor localization or uptake?

被引：280

作者：

Pirollo, Kathleen F. ^{[1
]}

Chang, Esther H. ^{[1
]}

机构：

[1] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA

来源：

TRENDS IN BIOTECHNOLOGY | 2008年 / 26卷 / 10期

关键词：

D O I：

10.1016/j.tibtech.2008.06.007

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inclusion of a tumor-targeting molecule in nanosized delivery systems increases their in vivo efficacy. However, the biodistribution and pharmacokinetics of the uptake of such particles have not yet been well addressed. Several recent papers have suggested that tumor-targeting ligands function primarily to increase intracellular uptake of the nanocomplex and do not influence tumor localization. However, other reports indicate that they do play a role in the accumulation in the tumor. One difference might be the presence or absence of poly-[ethylene glycol] (PEG) in the complex and its impact on the enhanced permeability and retention (EPR) effect. Further studies are clearly needed to more fully elucidate the influence of composition on tumor-targeted, systemic delivery of nanoparticles.

引用

页码：552 / 558

页数：7

共 40 条

[1]

Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121

[2] Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging [J].

Bartlett, Derek W. ;

Su, Helen ;

Hildebrandt, Isabel J. ;

Weber, Wolfgang A. ;

Davis, Mark E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) :15549-15554

[3] The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas [J].

Cao, Yue ;

Nagesh, Vijaya ;

Hamstra, Daniel ;

Tsien, Christina I. ;

Ross, Brian D. ;

Chenevert, Thomas L. ;

Junck, Larry ;

Lawrence, Theodore S. .

CANCER RESEARCH, 2006, 66 (17) :8912-8917

[4] Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery [J].

Cheng, Jianjun ;

Teply, Benjamin A. ;

Sherifi, Ines ;

Sung, Josephine ;

Luther, Gaurav ;

Gu, Frank X. ;

Levy-Nissenbaum, Etgar ;

Radovic-Moreno, Aleksandar F. ;

Langer, Robert ;

Farokhzad, Omid C. .

BIOMATERIALS, 2007, 28 (05) :869-876

[5] The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer [J].

Daniels, Tracy R. ;

Delgado, Tracie ;

Rodriguez, Jose A. ;

Helguera, Gustavo ;

Penichet, Manuel L. .

CLINICAL IMMUNOLOGY, 2006, 121 (02) :144-158

[6] Selective gene delivery for cancer therapy using cationic liposomes: In vivo proof of applicability [J].

Dass, Crispin R. ;

Choong, Peter F. M. .

JOURNAL OF CONTROLLED RELEASE, 2006, 113 (02) :155-163

[7] Cellular dynamics of EGF receptor-targeted synthetic viruses [J].

de Bruin, Karla ;

Ruthardt, Nadia ;

von Gersdorff, Katharina ;

Bausinger, Ralf ;

Wagner, Ernst ;

Ogris, Manfred ;

Braeuchle, Christoph .

MOLECULAR THERAPY, 2007, 15 (07) :1297-1305

[8] Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting [J].

De Paula, Daniel ;

Bentley, M. Vitoria L. B. ;

Mahato, Ram I. .

RNA, 2007, 13 (04) :431-456

[9] In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles:: Effect of MePEG molecular weight and particle size [J].

Fang, C ;

Shi, B ;

Pei, YY ;

Hong, MH ;

Wu, J ;

Chen, HZ .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (01) :27-36

[10] Pros and cons of the liposome platform in cancer drug targeting [J].

Gabizon, Alberto A. ;

Shmeeda, Hilary ;

Zalipsky, Samuel .

JOURNAL OF LIPOSOME RESEARCH, 2006, 16 (03) :175-183

← 1 2 3 4 →